CNS PHARMACEUTICALS INC (CNSP) Stock Earnings & Estimates
USA - NASDAQ:CNSP - US18978H5081 - Common Stock
8.2525 USD
+0.2 (+2.52%)
8.4 USD
+0.15 (+1.79%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A 37.36% | N/A 28.78% | |||||||||
| EBITDA YoY % growth | N/A | N/A | -3.83M | -9.44M -146.48% | -14.48M -53.39% | -15.26M -5.39% | -18.861M -23.60% | -14.899M 21.01% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -220K | -880K -300.00% | -3.83M -335.23% | -9.45M -146.74% | -14.49M -53.33% | -15.27M -5.38% | -18.865M -23.54% | -14.902M 21.01% | N/A 4.01% | N/A 0.54% | N/A -38.67% | N/A 347.98% | N/A 92.34% | N/A 43.39% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -42,750.00 -408.02% | -40,500.00 5.26% | N/A 99.97% | N/A -17.65% | N/A -3,808.00% | N/A 92.81% | N/A 69.80% | N/A 10.02% | N/A -171.18% | N/A | N/A |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -7.24 95.18% | -6.69 93.98% | -7.76 | -1.26 80.30% |
| Revenue Q2Q % growth | ||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -3.294M 41.49% | -3.395M -6.09% | -2.885M 33.50% | -3.01M -24.93% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -6.42 | -9.79 | 3.37 | 34.44% |
| Q4 2024 Q2Q % growth | -111.00 | -118.24 | 7.24 | 6.12% |
| Q3 2024 Q2Q % growth | -150.00 -13,788.89% | -61.20 | -88.80 | -145.10% |
| Q3 2023 Q2Q % growth | -1.08 99.98% | % | ||
| Q1 2023 Q2Q % growth | -2.59 99.95% | % | ||
| Q4 2022 Q2Q % growth | 99.97% | -2.45 | % | |
| Q3 2022 Q2Q % growth | -6,750.00 35.71% | -6,120.00 | -630.00 | -10.29% |
| Q2 2022 Q2Q % growth | -6,750.00 40.00% | -6,120.00 | -630.00 | -10.29% |
| Q1 2022 Q2Q % growth | -5,250.00 53.33% | -8,415.00 | 3,165.00 | 37.61% |
| Q4 2021 Q2Q % growth | -7,500.00 44.44% | -12,240.00 | 4,740.00 | 38.73% |
| Q3 2021 Q2Q % growth | -10,500.00 -16.67% | -12,431.25 | 1,931.25 | 15.54% |
| Q2 2021 Q2Q % growth | -11,250.00 | -9,945.00 | -1,305.00 | -13.12% |
| Q1 2021 Q2Q % growth | -11,250.00 -25.00% | -9,180.00 | -2,070.00 | -22.55% |
| Q4 2020 Q2Q % growth | -13,500.00 -5.88% | -8,988.75 | -4,511.25 | -50.19% |
| Q3 2020 Q2Q % growth | -9,000.00 -140.00% | -9,562.50 | 562.50 | 5.88% |
| Q2 2020 Q2Q % growth | -11,250.00 | -6,120.00 | -5,130.00 | -83.82% |
| Q1 2020 Q2Q % growth | -9,000.00 | -7,650.00 | -1,350.00 | -17.65% |
| Q4 2019 Q2Q % growth | -12,750.00 | -2,295.00 | -10,455.00 | -455.56% |
| Q3 2019 Q2Q % growth | -3,750.00 | -2,295.00 | -1,455.00 | -63.40% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | -1026.19% | 87.55% | -49.37% |
| Revenue | N/A | N/A | N/A | N/A |